Key result
Low-dose colchicine reduces the risk of recurrent non-fatal ischemic events in patients with coronary heart disease by suppressing residual inflammation, without significantly affecting overall or cardiovascular mortality.
Why the study?
Suppressing inflammatory activity to reduce residual inflammatory risk in atherosclerotic cardiovascular diseases remains an urgent and unresolved problem.
Does colchicine improve prognosis in patients with coronary heart disease?
Does colchicine improve prognosis in patients with coronary heart disease?
This review highlights the emerging role of colchicine in reducing residual inflammatory risk and improving outcomes in patients with coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Supports colchicine for nonfatal ischemic risk reduction in CHD; leaves open confirmation in prospective RCTs.
Енисеева et al. (2021) conducted a review in Coronary heart disease. Colchicine vs. Standard therapy or placebo was evaluated. Low-dose colchicine reduces the risk of recurrent non-fatal ischemic events in patients with coronary heart disease by suppressing residual inflammation, without significantly affecting overall or cardiovascular mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: